Skip to main content

Search

Site

Search results

10 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 1

Oct 18, 2019 Belgium If approved by the European Commission, esketamine nasal spray will offer the first new mechanism of action in 30 years to treat major depressive disorder (MDD) In the phase III clinical development programme with flexible dosing, ...

Sep 09, 2019 United States Global clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies TITUSVILLE, NJ, SEPTEMBER 9, 2019 – The Janssen Pharmaceutical Companies of ...

Dec 19, 2019 Belgium Esketamine nasal spray offers the first new mechanism of action for an antidepressant in 30 years EC approval is based on data from a clinical trial programme in adult patients with treatment-resistant major depressive disorder, ...

Feb 12, 2019 United States If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people ...

Oct 02, 2019 United States If approved, SPRAVATO ® would be the first treatment for this severely ill population 1 who historically have been excluded from antidepressant clinical trials Submission is based on data from the ASPIRE I & II trials ...

May 21, 2019 United States NEW ORLEANS, May 21, 2019  -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a   new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting ...

Jan 15, 2020 Belgium In two pivotal Phase 3 trials, SPRAVATO ® ▼ combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms in patients with major depressive disorder who have current suicidal ...

Aug 03, 2020 United States- SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population- Approval is based on Phase 3 data showing ...

Mar 05, 2019 United States SPRAVATO™ uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3    In short- and long-term clinical trials, those who received SPRAVATO™ and a newly initiated oral antidepressant achieved ...

OUR Commitment to Multiple Sclerosis   Thank you for visiting the Janssen Neuroscience R&D MSVirtual2020 Newsroom! Below, please find our meeting news, social feeds, and more information about our progress and commitment to developing innovative ...

10 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 1